Partners at Ironbridge participated in the £1.3m capital raise. David Alexander has joined the Board as a non-executive director. Censo Biotechnologies enables the discovery and development of new targeted treatments for disease by using stem cell technology to predict how drugs will behave across a given population.
Ironbridge Capital Partners invested in Biomin Technologies (www.biomin.co.uk) in September 2018. Biomin has patent-protected technology for a bioactive glass which, when incorporated in dental products such as toothpaste, has the effect of reducing sensitivity, rebuilding enamel and enabling better resistance to ‘acid attack’ caused by fruit juices and fizzy drinks.
Ironbridge participated in the £650k funding round of fintech business MarktoMarket (www.marktomarket.io) which provides an end-to-end solution to produce the most efficient and auditable private company valuations.
Deal: Principal Investment Size: Undisclosed Date: January 2017 Ironbridge Partner David Alexander has led the acquisition of Perth-based Edwards Engineering by investment group Cartalex as part of a plan to build a significant new business in the engineering sector in England and Scotland. Investors, David Alexander and Industry veteran Ben Carter, will both sit on the […]
IRONBRIDGE MONTHLY ROUNDUP - April 2015
IRONBRIDGE MONTHLY ROUNDUP - March 2015
IRONBRIDGE MONTHLY ROUNDUP - February 2015
IRONBRIDGE MONTHLY ROUNDUP - January 2015
Central Working Victoria, Eccleston Yards, 25 Eccleston Place, London SW1W 9NF
Tel: +44 (0) 7734 031 060
Ironbridge Capital Partners LLP is registered in the UK at Central Working Victoria, Eccleston Yards, 25 Eccleston Place, London SW1W 9NF Company number: OC308373.
© 2020 Ironbridge Capital Partners LLP